Skip to main content

Articles

Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer

Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion

The Role of Non-Statin Lipid-Lowering Therapy in Older Adults with ASCVD

Interview with the Innovators

A Passion for Scientific Innovation and a Company Culture That Values Customers Drive the Teams at Genmab to Discover Cutting-Edge Solutions for People with Cancer

Conference Highlights ASCO

Trastuzumab Deruxtecan a New Standard for Patients with HER2-Low Metastatic Breast Cancer

Minimizing the Burden of Cardiovascular Disease: A Need for Lipid-Lowering Strategies Beyond Statins

Interview with the Innovators

Genmab Unleashes the Power of Strategic Alliances to Advance the Science of Therapeutic Antibodies for People with Cancer

Convergence: Up Close and Personal

David B. Nash, MD, MBA

Clinical, Original Research

Real-World Treatment Patterns and Healthcare Costs Among Patients with FL with Early Treatment Failure of First-Line Chemoimmunotherapy

Lori A. Leslie, MD; Bruno Emond, MSc; Marie-Hélène Lafeuille, MA; Maude Vermette-Laforme, BSc; Patrick Lefebvre, MA; Qing Huang, PhD, MHS

Business, Original Research

Budget Impact of Intravenous Cetirizine Hydrochloride for the Treatment of Acute Urticaria in the Emergency Department Setting

Lisa M. Bloudek, PharmD, MS; LoAn K. Ho, PharmD; Neha Kapur, PharmD; Lonnie D. Brent, PharmD

6
7
8
9
10
11
12

Page 9 of 246
Results 81 - 90 of 2456